Viking Therapeutics, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Viking Therapeutics priced 7,857,143 common shares at $35.00/share (7.6% below $41.65 prior close) for ~$275M gross proceeds, plus $225M of 2.00% convertible notes due 2032 at 100% of par (conversion price ~$50.75, 45% premium). Lead underwriters: Morgan Stanley and J.P. Morgan. Settlement Sept 25, 2026. Net proceeds ~$258M (equity) and ~$218M (convertible notes) after underwriting discounts of $2.10/share (equity) and 3.0% (notes). Proceeds for VK2735 and VK3019 clinical development and general corporate use.
Why this rating
Combined ~$476M gross capital raise is ~16% of $3B market cap—material for funding but routine for biotech at this stage. No acquisition, no restructuring, no going concern issue.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.